Active substance
Arformoterol
- US FDA 18
- US price lines 4
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ARFORMOTEROL TARTRATE | EQ 0.015MG BASE/2ML | solution · inhalation | CIPLA | Prescription | 22 Jun 2021 |
| ARFORMOTEROL TARTRATE | EQ 0.015MG BASE/2ML | solution · inhalation | ADAPTIS | Prescription | 22 Jun 2021 |
| ARFORMOTEROL TARTRATE | EQ 0.015MG BASE/2ML | solution · inhalation | LUPIN | Prescription | 7 Feb 2022 |
| ARFORMOTEROL TARTRATE | EQ 0.015MG BASE/2ML | solution · inhalation | RITEDOSE CORP | Prescription | 2 Mar 2022 |
| ARFORMOTEROL TARTRATE | EQ 0.015MG BASE/2ML | solution · inhalation | ALEMBIC | Prescription | 10 May 2022 |
| ARFORMOTEROL TARTRATE | EQ 0.015MG BASE/2ML | solution · inhalation | SUN PHARM | Prescription | 26 May 2022 |
| ARFORMOTEROL TARTRATE | EQ 0.015MG BASE/2ML | solution · inhalation | MANKIND PHARMA | Prescription | 15 Nov 2022 |
| ARFORMOTEROL TARTRATE | EQ 0.015MG BASE/2ML | solution · inhalation | WILSHIRE PHARMS INC | Prescription | 28 Nov 2022 |
| ARFORMOTEROL TARTRATE | EQ 0.015MG BASE/2ML | solution · inhalation | AIPING PHARM INC | Prescription | 2 Apr 2024 |
| ARFORMOTEROL TARTRATE | EQ 0.015MG BASE/2ML | solution · inhalation | NEOCUBES PHARMA | Prescription | 17 May 2024 |
| ARFORMOTEROL TARTRATE | EQ 0.015MG BASE/2ML | solution · inhalation | DR REDDYS | Prescription | 3 Jun 2024 |
| ARFORMOTEROL TARTRATE | EQ 0.015MG BASE/2ML | solution · inhalation | LEXENPHARM | Prescription | 18 Nov 2024 |
| ARFORMOTEROL TARTRATE | EQ 0.015MG BASE/2ML | solution · inhalation | AUCTA | Prescription | 3 Feb 2025 |
| ARFORMOTEROL TARTRATE | EQ 0.015MG BASE/2ML | solution · inhalation | MICRO LABS | Prescription | 7 Mar 2025 |
| ARFORMOTEROL TARTRATE | EQ 0.015MG BASE/2ML | solution · inhalation | SABA ILAC SANAYI | Prescription | 25 Apr 2025 |
| BROVANA | EQ 0.015MG BASE/2ML | solution · inhalation | LUPIN | Discontinued | 6 Oct 2006 |
| ARFORMOTEROL TARTRATE | EQ 0.015MG BASE/2ML | solution · inhalation | GLENMARK PHARMS LTD | Discontinued | 22 Jun 2021 |
| ARFORMOTEROL TARTRATE | EQ 0.015MG BASE/2ML | solution · inhalation | TEVA PHARMS USA | Discontinued | 9 Nov 2021 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ARFORMOTEROL 15 MCG/2 ML SOLN | $0.63275 | per ML | 23 Sep 2026 |
| US NADAC | ARFORMOTEROL 15 MCG/2 ML SOLN | $0.6202 | per ML | 23 Sep 2026 |
| US NADAC | BROVANA 15 MCG/2 ML SOLUTION | $9.67343 | per ML | 22 Oct 2025 |
| US NADAC | BROVANA 15 MCG/2 ML SOLUTION | $9.74999 | per ML | 22 Oct 2025 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 29 May 2019 BROVANA — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.